How to Buy Insulet Stock
Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
Insulet stock last closed at $226.50, up 0.54% from the previous day, and has increased 29.94% in one year. It has overperformed other stocks in the Medical Devices industry by 0.39 percentage points. Insulet stock is currently +80.02% from its 52-week low of $125.82, and -0.33% from its 52-week high of $227.26.
As of Sep 10, 2024, there are 70.12M PODD shares outstanding. The market cap of PODD is $15.88B. In the last 24 hours, 894,552 PODD shares were traded.
How to Buy Insulet Stock
Not sure how to invest in Insulet stock? Here's how.
- Decide where to buy Insulet stock: You need to choose a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you determine where to buy Insulet stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Put funds into your brokerage account: Choose your payment method and add your info.
- Research Insulet stock: The Insulet ticker symbol is PODD. Is Insulet stock a good investment? Should you buy shares of PODD? How do PODD's underlying business fundamentals look? Do top analysts think Insulet is a good buy? Why has PODD's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if PODD is a good stock to buy).
- Execute your PODD purchase: Decide if you will purchase PODD shares at the current market price or use a limit order to buy PODD shares at a given price.
- Get notifications regarding your PODD position: Create a watchlist to monitor your position in Insulet shares.
Step 1: Decide where to buy Insulet stock
You will need an online brokerage account to access the NASDAQ market and buy PODD stock.
Our favorite brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Energy, New York to Hong Kong — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen the right brokerage, you need to fill out some personal information so you are able to buy PODD stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to create your new brokerage account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have filled out your info on a good online stock trading app, your next step is to transfer the money for your investment:
Watch the walkthrough below to see the process of depositing funds into your new investment account.
Step 4: Research Insulet stock
Once you have chosen the best place to buy Insulet stock, it's critical to analyze their stock before you invest, so you can wrap your head around the risk and opportunity.
Overview of key PODD info
PODD Overview
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis.
You can view all of the due diligence checks on PODD's stock page.
What is the fair value of PODD stock?
You can use a variety of different financial metrics, analyses, models, and charts to gauge PODD's true value.
Using relative valuations ratios:
- PODD could be undervalued based on its P/E ratio of 40.09x, relative to Medical Devices industry P/E ratio of 42.62x
- PODD could be overvalued based on its P/B ratio of 15.91x, relative to Medical Devices industry P/B ratio of 4.08x
You can access additional valuation analysis on PODD's stock here.
A quick look at PODD Financials
Passed Financial Due Diligence Checks:
- Total PODD debt is lower than 5 years ago, relative to shareholder equity.
- PODD profit margin has gone up from 4.3% to 21.1% in the past year.
- There are more short-term assets than short-term liabilities on the PODD balance sheet.
- PODD's operating cash flow of $285.30M allows it to safely service it's debt of $1.40B.
- There are more short-term assets than long-term liabilities on the PODD balance sheet.
- PODD earnings of $306.30M is not enough to cover its interest payments.
Failed Financial Due Diligence Checks:
- PODD has a relatively high debt to equity ratio of 1.89.
Is it a good time to buy Insulet stock, according to analysts?
Out of 8 Wall Street analysts who track PODD, the consensus analyst rating on PODD is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Latest PODD Analyst Ratings
Kyle Rose, a top 12% analyst from Canaccord Genuity maintains PODD with a strong buy rating and raises their PODD price target from $226.00 to $234.00, on May 10, 2024.
Canaccord Genuity's Kyle Rose raised their price target on Insulet (NASDAQ: PODD) by 3.5% from $226 to $234 on 2024/05/10. The analyst maintained their Strong Buy rating on the stock.
The analyst's price target hike followed an assessment of Insulet's 2024/05/09 dated Q1 2024 earnings report.
Rose said their enthusiasm is growing because they see a "significant T2 opportunity that could provide a multi-year tailwind for the company."
Earnings Report
For Q1 2024, Insulet reported:
- EPS of $0.73, which beat the Zacks Consensus Estimate of $0.39 and, by 114.7%, Q1 2023’s $0.34.
- Revenue of $441.7M, which beat the Zacks Consensus Estimate of $423.5M and, by 23.3%, Q1 2023’s $358.1M.
- Gross margin of 69.5%, up 460 bps Y/Y.
- Operating margin of 12.9%, up 740 bps Y/Y.
Management guided:
For Q2 2024:
- Revenue growth of 15% to 18%.
For FY 2024:
- Revenue growth of 14% to 18%, up from prior guidance of 12% to 17%.
- Gross margin of 68% to 69%.
- Operating margin of 13.5%, up from prior guidance of 13%.
President & CEO Jim Hollingshead commented: “We are pleased with our strong Q1 results, which underscore the strength of our advanced technology platform and deep competitive advantages.
“During the quarter, we achieved strong new customer starts and gained market share globally, and expanded access to Omnipod 5 through our commercial launches with Dexcom’s G7 in the U.S. and with sensor of choice - Abbott’s Freestyle Libre 2 Plus and G6 - in two European countries.
“As a result of our momentum, upcoming catalysts and operational execution, we have increased both our revenue and operating margin outlook for the year.
“Insulet is well positioned to drive continued profitable growth while delivering on our mission to improve the lives of people with diabetes.”
Jayson Bedford, a top 14% analyst from Raymond James maintains PODD with a buy rating and lowers their PODD price target from $218.00 to $213.00, on May 10, 2024.
Mike Polark, a top 18% analyst from Wolfe Research upgrades PODD to a buy rating and announces their PODD price target of $200.00, on May 7, 2024.
You can dive deeper into what analysts are projecting on the Insulet stock forecast page.
PODD Trading Indicators
PODD Performance Metrics
Last year, PODD earnings were $395.30M. In the past five year, PODD's earnings have gone up by 81.1% per year. This was faster than the Medical Devices industry average of 9.19%.
Last year, PODD revenue was $1.87B. During the last 5 year, PODD's revenue has grown by 23.47% per year. This was faster than the Medical Devices industry average of 11.13%.
You can analyze PODD's earnings and revenue performance here.
Who is buying/selling PODD?
Over the last year, insiders at PODD have sold more shares than they have bought.
Timothy J. Scannell, Director of PODD, was the latest PODD insider to sell. They sold $1,129,200.00 worth of PODD stock on Sep 10, 2024.
Research more about who owns PODD stock here.
Does PODD provide a stable income stream?
No, Insulet doesn't provide an income stream by paying out dividends.
What others are saying about PODD
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your PODD purchase
There are two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific price limit, place a limit order.
Press the Open button and eToro will place your order.
If you require more assistance buying stocks on eToro, watch the helpful video below:
Step 6: Get notifications regarding your PODD position
Now that you own some shares in PODD, you'll want to stay up-to-date on your new investment.
Start a watchlist to get alerted to the latest events about your PODD stock.
PODD Feed
How to Buy Stock in Insulet
To reiterate, here are the 6 steps for buying Insulet stock:
- Decide where to buy Insulet stock
- Open a brokerage account
- Put funds into your brokerage account
- Research Insulet stock
- Execute your PODD purchase
- Get notifications regarding your PODD position
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to track your investment in Insulet, create a watchlist today.
Related Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.